Welcome to our dedicated page for Immunocore Holdings Plc SEC filings (Ticker: IMCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunocore Holdings plc (IMCR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a Nasdaq‑listed foreign private issuer. Immunocore files current reports on Form 8‑K, annual reports on Form 10‑K and other documents that describe its financial performance, risk factors, capital structure and progress across its ImmTAX platform in oncology, infectious diseases and autoimmune diseases.
Recent Form 8‑K filings dated August 7, 2025 and November 6, 2025 report the release of quarterly financial results and business updates, including net product sales from KIMMTRAK, cash and marketable securities, and status of key clinical trials such as TEBE‑AM, PRISM‑MEL‑301 and ATOM. These filings also incorporate press releases as exhibits, giving additional detail on KIMMTRAK approvals, launches and the company’s pipeline of ImmTAC, ImmTAV and ImmTAAI candidates.
On this page, investors can review Immunocore’s periodic reports to understand how the company accounts for revenue from its commercial product, funds research on TCR bispecifics for HIV and HBV, and advances autoimmune programs like IMC‑S118AI and IMC‑U120AI. Form 4 and related insider transaction filings, when available, can be used to track equity dealings by directors and senior stakeholders.
Stock Titan enhances these IMCR filings with AI‑powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on KIMMTRAK commercialization, clinical trial commitments, liquidity, and material events disclosed under U.S. securities laws, while still allowing access to the full original SEC text for detailed analysis.
David M. Berman, Head of R&D at Immunocore Holdings plc (IMCR), reported option exercises and open-market sales in a Form 4. Under a Rule 10b5-1 plan adopted May 9, 2025, the filing shows exercises of employee share options at a $17.46 exercise price to acquire 22,532 ordinary shares on 09/12/2025 and 200 ordinary shares on 09/15/2025. Concurrently, the filing reports sales of 21,232 shares at a weighted-average price of $35.63, 1,300 shares at $36.31, and 200 shares at $35.01, executed on 09/12/2025 and 09/15/2025. The filing is signed by an attorney-in-fact.
Insider notice to sell 135,000 American Depositary Shares (ADS) of Immunocore Holdings plc (IMCR) is reported on Form 144. The shares are to be sold through J.P. Morgan Securities LLC on 09/10/2025 with an aggregate market value of $4,939,650. The filing shows the ADS were acquired and will be sold on 09/10/2025 via a stock option exercise, with payment made in cash. The issuer has 50,387,068 ADS outstanding per the form. The filer reports no other securities sold in the past three months and certifies no undisclosed material adverse information.
Primecap Management Co/CA reports beneficial ownership of 3,772,234 ADRs of Immunocore Holdings plc, representing 7.51% of the class. The filing shows Primecap is an investment adviser organized in the United States and holds sole voting power for 3,746,574 shares and sole dispositive power for 3,772,234 shares. The statement clarifies these securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The document identifies the ADR class and provides the filer’s principal business address.
Filing: Schedule 13G/A (Amendment No. 5) reporting for Immunocore Holdings plc (CUSIP 45258D105).
Key facts: Wellington Management Group LLP and affiliated entities report beneficial ownership of 5,132,898 shares of Immunocore common stock (reported as 10.2% / 10.22% of the class). Reported ownership shows no sole voting or dispositive power; shared voting power is reported as 4,958,998 and shared dispositive power as 5,132,898. The filing notes these shares are owned of record by clients of Wellington investment advisers and identifies Vanguard Health Care Fund as an exception referenced in Item 6. The issuer address and filer addresses are included; the filing is signed by Taisia Lowe on 08/05/2025.